RLAY (Relay Therapeutics) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RLAY Relay Therapeutics Inc RLAY
53 GF Score
Price $20.17
GF Value $3.80
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Relay Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RLAY vs CELC, VKTX, DYN: Short Interest Comparison

For the Biotechnology subindustry, Relay Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relay Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relay Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Relay Therapeutics's Short Interest falls into.


RLAY
53GF Score
Relay Therapeutics Inc RLAY
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Relay Therapeutics (RLAY) Overvalued in 2026?

Based on GuruFocus' analysis, Relay Therapeutics stock appears to be overvalued. The current stock price of $20.17 is trading 430.7% above its estimated GF Value™ of $3.80. GuruFocus considers Relay Therapeutics to be Significantly Overvalued.

Key valuation signals for RLAY:

  • Short Interest:
  • GF Value™: $3.80 vs. price of $20.17 (430.7% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the RLAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relay Therapeutics Business Description

Address 60 Hampshire Street, Cambridge, MA, USA, 02139
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
53GF Score

Get the complete analysis for RLAY

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.17
Price
$3.80
GF Value